Phase 1 N=24 A Phase Ib/II in Patients With Acute Ischemic Stroke
Ischemic Stroke
Primary: Maximum Tolerated Dose (MTD) of DDFPe Evaluated by Number of Dose Limiting Toxicities — 0; 0; 0; 0 Dose Limiting Toxicities
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=35 Safety Study of Post Intravenous tPA Monitoring in Ischemic Stroke
Stroke · Ischemic Stroke
Primary: Number of Participants Needing ICU Care/Interventions Within the First 24 Hours of IV tPA Administration — 0 Participants
N/A N=1,196 Coordinated, Collaborative, Comprehensive, Family-based, Integrated, Technology-enabled Stroke Care
Stroke · Stroke, Ischemic · Stroke, Acute
Primary: Stroke Impact Scale (SIS) at 12-months Post-discharge — 80.42; 83.85 Score
N/A N=16 American Heart Association- Stroke/Hypoxia Study
Stroke
Primary: Number of Participants With Adverse Events — 1; 11; 2; 10 Participants
N/A N=31 Multifocal Brain Magnetic Stimulation in Chronic Ischemic Stroke
Stroke
Primary: Changes in Brain Activation — 48.5; -30 voxels
N/A N=20 Motor and Neurophysiological Changes After Ischemic Conditioning in Individuals With Stroke
Stroke
Primary: Change in Corticomotor Excitability — 0.38; 0.37; 0.41; 0.37 millivolt (mV)
N/A N=5,882 Comprehensive Post-Acute Stroke Services
Stroke · Transient Ischemic Attack
Primary: Stroke Impact Scale (SIS-16) — 79.9; 80.6 score on a scale
N/A N=147,716 Comparative Effectiveness of Rehabilitation Services for Survivors of Acute Ischemic Stroke
Ischemic Stroke
Primary: Number of Participants Receiving Inpatient, Home, or Community Based Rehabilitation Services — 76720; 32350 participants
Phase 3 N=3,876 Insulin Resistance Intervention After Stroke Trial
Stroke · Myocardial Infarction · Diabetes
Primary: Recurrent Fatal or Non-fatal Stroke, or Fatal or Non-fatal Myocardial Infarction — 175; 228 participants — p=.0067
Phase 4 N=188 Treatment for Post-Stroke Depression
Stroke · Depression
Primary: Twelve Week Depression Outcomes — 10.6 HAM-D depression score
Phase 4 N=80 Human Urinary Kallidinogenase Improve Short Term Motor Functional Outcome of Acute Ischemia Stroke Patients
Stroke, Acute
Primary: Myelin Basic Protein (MBP) Comparison Between the Two Groups Before and After Treatment — 0.42; 0.64; 0.41; 0.71 pg/ml
N/A N=1,500 Remote Ischemic Conditioning in Patients With Acute Stroke (RESIST)
Stroke, Acute · Ischemic Stroke · Hemorrhagic Stroke
Primary: Modified Rankin Scale at 3 Months in Acute Stroke (AIS and ICH) — 2; 1 units on a scale
N/A N=12,551 1-year Clinical Outcomes in Recombinant Tissue Plasminogen Activator (Rt-PA) Treated Chinese Acute Ischaemic Stroke (AIS) Patients
Stroke
Primary: All-cause Mortality at 1 Year (Percentage of Patients With Modified Rankin Scale (mRS) Score =6) — 11.1; 12.2 Percentage of Participants — p=0.183
Phase 2 N=3 Histamine Glutamate Antagonism in Stroke
Acute Cerebrovascular Accident · Cerebral Edema
Primary: Modified Rankin Score
Phase 2 N=31 NeuroCognition After Carotid Recanalization
Cognition Disorder · Stroke · Occlusion Carotid
Primary: Change in Montreal Cognitive Assessment (MoCA) Score — 0.56; 1.38; -0.75; 0.50 score on a scale
Phase 2 N=83 A Phase 2b Study of Dalfampridine 10mg Extended Release Tablet in Subjects With Chronic Deficits After Ischemic Stroke
Ischemic Stroke
Primary: Safety and Tolerability of Dalfampridine-ER in Subjects With Chronic Deficits After Ischemic Stroke Assessed by Number of Treatment Emergent Adverse Events (TEAEs) — 30…
Phase 2 N=18 Dietary Nitrate Supplements and Ischemic Stroke Recovery
Stroke · Ischemic Stroke · Cerebrovascular Accident
Primary: Adherence With Intervention — 93.5; 100 percentage of participants — p=0.058
Phase 2 N=40 Percutaneous Recanalization in Ischemic Stroke Management (PRIISM): A Feasibility Clinical Study
Ischemic Stroke
Primary: Technical Device Success by as Assessed by the Percentage of Participants Which Established at Least TIMI 2 Flow Upon Deployment of the System Across the Occlusion and…
Phase 4 N=401 Edaravone-Sodium Ozagrel Comparative Post-Marketing Study on Acute Ischemic Stroke
Cerebral Infarction
Primary: the Rate of Patients With a Modified Rankin Scale Score of 0-1 — 109; 98; 46; 39 participants
Phase 2 N=79 Study of Allogeneic Umbilical Cord Blood Infusion for Adults With Ischemic Stroke
Stroke · Stroke, Acute · Brain Injury, Acute
Primary: Shift in Modified Rankin Scale (mRS) — 1; 1 score on a scale — p=0.71
N/A N=54 Post Marketing Study to Evaluate the NIMBUS Device
Cerebral Stroke
Primary: Percentage of Participants With Successful Revascularization With NIMBUS Device — 68.6 Percentage of participants
N/A N=4 Repetitive Transcranial Magnetic Stimulation Use in Acute Stroke
Stroke
Primary: Percent Change From Baseline in Jebsen Taylor Hand Function Test Scores — -23.0; 0 percentage of change from baseline
Phase 3 N=14 Neuroprotection in Acute Ischemic Stroke
Stroke, Ischemic
Primary: Number of Participants With Favorable Outcome on the Simplified Modified Rankin Scale (sMRSq) — 5; 7; 1; 1 participants
Phase 2 N=18 Combination Anti-Platelet and Anti-Coagulation Treatment After Lysis of Ischemic Stroke Trial (CATALIST)
Ischemic Stroke
Primary: Symptomatic Intracerebral Hemorrhage (ICH) — 1; 1 participants
Phase 2 N=18 Positional Therapy After Stroke
Sleep Apnea · Stroke
Primary: Apnea-hypopnea Index — 27; 39 events/hr — p=0.011
N/A N=185 A Novel Transition Program to Reduce Disability After Stroke
Ischemic Stroke · Hemorrhagic Stroke
Primary: Reintegration to Normal Living Index (RNLI) — 60.8; 61.2; 74.8; 73.9 score on a scale — p=0.76
N/A N=23 Treatment of Chronic Stroke With IpsiHand
Stroke
Primary: Change in Action Research Arm Test (ARAT) Score — 6.2 units on a scale — p=0.002
Phase 2 N=120 Blood Pressure After Endovascular Stroke Therapy-II
Acute Stroke · Endovascular Thrombectomy
Primary: Final Infarct Volume — 46.4; 50.7; 32.4 Cubic Centimeters
Phase 2 N=277 Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke
Acute Ischemic Stroke
Primary: Percentage of Participants With Composite Global Measure of Functional Disability Excellent Outcome at Day 90 — 54.1; 41.5; 39.9 percentage of participants — p=0.086
Phase 1 N=9 TMS and Exercise for Post-stroke Pain
Chronic Post-stroke Headache
Primary: Change in Modified Rankin Scale From Baseline to Follow-up 30 Days After Last Intervention — 0; 1 units on a scale — p=0.896